Sage Therapeutics (NASDAQ:SAGE) is reportedly suing Biogen (NASDAQ:BIIB) over enforcement of a standstill agreement in the ...

Sage Therapeutics has sued Biogen in Delaware court, one week after receiving a $469 million buyout offer from the larger ...

Sage Therapeutics Inc. sued Biogen Inc. on Friday, a week after the biotech giant made an unsolicited offer to acquire the ...

Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

The owner of Sage Screen Printing Studio shares how he started "West Wing" a Ravens fan group in Los Angeles.

J&J, GSK, Eli Lilly and others struck high-value transactions in the early days of biopharma’s annual kickoff conference.

While Biogen has made an opportunistic bid for partner Sage, its top executive seemed to play down the urgency for his ...

Sage Therapeutics' financials indicate a need for additional funding in 2025, risking dilution and further financial ...

Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE – Get Free Report) have been assigned a consensus rating of “Hold” from the ...

RBC Capital Mkts has recently raised SAGE Therapeutics Inc (SAGE) stock to Sector Perform rating, as announced on November 21, 2024, according to Finviz. Earlier, on October 10, 2024, Raymond James ...

Health-care companies rose amid deal activity. Shares of mental-illness drug developer Intra-Cellular rallied after health-care conglomerate Johnson & Johnson agreed to buy it for $15 billion, ...